Clinical Trial Update: A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency [Phase 1]

View source ↗

Summary

A Phase 1 study evaluated multiple doses of abiraterone acetate in adult women with 21-hydroxylase deficiency (congenital adrenal hyperplasia).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Adrenal Hyperplasia

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: 21-hydroxylase Deficiency | Phase 1 | Status: COMPLETED